Anti-Microbial Resistance Market: By Technology (Microbiology Culture, Immunoassay, PCR, NGS, Mass Spectrometry, Rapid & Point of Care, Others), By Pathogen (Drug Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRNTS), Others), End User: (Hospitals, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Others), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Anti-Microbial Resistance Market size was valued at USD 9,278.2 million in 2022 and is poised to grow at a significant CAGR of 6.1% over 2023-2029. Antimicrobial resistance has emerged as the most serious threat to public health and is now considered as a global burden. Rapid diagnostic tests that identify microorganisms at high risk of developing drug resistance, assess antimicrobial susceptibility, and distinguish viral from bacterial infections might help guide effective treatment approaches. Rapid diagnostic tests also facilitate epidemiological surveillance by enabling the tracking of emerging resistant infectious diseases and their spread. To survive, bacteria can develop mechanisms known as antibiotic and antifungal resistance. The specific proteins that DNA instructs the germ to create determine the germ's resistance mechanisms. Bacteria and fungi include numerous types of resistance genes. The perfect convergence of resistance mechanisms in bacteria that are already difficult to treat can render all antibiotics and antifungals ineffective, resulting in untreatable diseases. Uncomfortably, bacteria resistant to antibiotics and antifungals may share such resistance mechanisms with other bacteria. The primary reasons driving market growth include the high disease burden from pathogens such as streptococcus pneumonia, MRSA, C. difficile infections, and others, additionally the rise in the occurrence of Antimicrobial Resistance (AMR) infections. Furthermore, increased demand for technologically sophisticated diagnostic solutions to manage AMR, as well as rising regulatory approvals of diagnostic devices, are expected to drive market expansion. For instance, in September 2021, MeMed announced that its MeMed BV diagnostic test obtained 510(k) approval from the U.S. FDA. The test is used to distinguish bacterial and viral infections in point-of-care settings. The growing issue of antibiotic resistance is projected to aid market growth. According to the CDC, approximately 2.8 million cases of AMR occur in the United States each year. Furthermore, according to the United States Pharmacopeial Convention, AMR kills around 700,000 people worldwide each year. Furthermore, if microbial infection detection and treatment are not appropriately handled, the number could reach 10 million per year by 2050.

 Anti Microbial Resistance Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

6.1%

Largest Market

Asia Pacific

Fastest Growing Market

North America
Anti-Microbial Resistance Market Dynamics

Rising incidence of infectious diseases coupled with epidemic & pandemic events.The growing number of epidemic outbreaks caused by infectious pathogens such as Haemophilus influenza, Neisseria meningitides, Streptococcus pneumoniae, Shigella, Vibrio cholera, Neisseria gonorrhoeae, and Salmonella serotype Typhi is also propelling the demand for antimicrobial resistance market. According to the WHO, TB is one of the top 10 causes of death and the leading cause of a single infectious agent. In 2018, 10 million people across the globe were estimated to be suffering from tuberculosis, of which 1.5 million people died due to the disease. Furthermore, according to the World Malaria Report 2019, estimated 228 million cases of malaria were diagnosed worldwide. The report further stated that the nineteen countries in sub-Saharan Africa and India carried almost 85% of the global malaria burden.

Key Features of the Reports

  • The anti-microbial resistance market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

 Anti Microbial Resistance Market Segmentation

By Technology
  • Microbiology Culture,
  • Immunoassay,
  • PCR,
  • NGS,
  • Mass Spectrometry,
  • Rapid & Point of Care,
  • Others.
By Pathogen
  • Drug Resistant Streptococcus Pneumoniae (DRSP)
  • Drug Resistant Campylobacter (DRC)
  • Clostridium Difficile (CD)
  • Methicillin Resistant Staphylococcus Aureus (MRSA)
  • Drug Resistant Neisseria Gonorrhoeae (DRNG)
  • Drug Resistant Salmonella (DRNTS)
  • Others
By End User
  • Hospitals
  • Diagnostic Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Others

Frequently Asked Questions

Some key players operating in the antimicrobial resistance diagnostics market include BIOMERIEUX, F. Hoffmann-La Roche Ltd, Abbott, BD, and Danaher among others.

The increasing risk of developing drug-resistant infections, the increasing introduction of technologically advanced tests, and government initiatives to reduce AMR disease burden are the major factors driving the antimicrobial resistance diagnostics market growth over the forecast period.

North America accounts for the largest share of the global Anti-Microbial Resistance market.

1. Executive Summary
2. Global Anti-Microbial Resistance Market Introduction
2.1. Global Anti-Microbial Resistance Market – Taxonomy
2.2. Global Anti-Microbial Resistance Market –Definitions
2.2.1. Technology
2.2.2. Pathogen
2.2.3. End User
2.2.4. Region
3. Global Anti-Microbial Resistance Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Anti-Microbial Resistance Market Dynamic Factors - Impact Analysis
3.6. Impact of COVID 19 on The Market
3.7. Three Forecast Scenarios - Pessimistic, Conservative and Opportunistic
3.8. Mapping Market Players Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations and Mergers
4. Global Anti-Microbial Resistance Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028
4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Anti-Microbial Resistance Market Forecast, By Technology, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
5.1. Microbiology Culture
5.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Immunoassay
5.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. PCR
5.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. NGS
5.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Mass Spectrometry
5.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Rapid & Point of Care
5.6.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Others
5.7.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
6. Global Anti-Microbial Resistance Market Forecast, By Pathogen, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
6.1. Drug Resistant Streptococcus Pneumoniae (DRSP)
6.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Drug Resistant Campylobacter (DRC)
6.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Clostridium Difficile (CD)
6.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Methicillin Resistant Staphylococcus Aureus (MRSA)
6.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Drug Resistant Neisseria Gonorrhoeae (DRNG)
6.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Drug Resistant Salmonella (DRNTS)
6.6.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Other
6.7.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
7. Global Anti-Microbial Resistance Market Forecast, By End User, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
7.1. Hospitals
7.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Diagnostic Laboratories
7.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Pharmaceutical & Biotechnology Companies
7.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Other
7.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global Anti-Microbial Resistance Market Forecast, By Region, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
8.1. North America
8.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Anti-Microbial Resistance Market - Opportunity Analysis Index, By Technology, Distribution Channel, End User, and Region, 2022 - 2028
9. North America Anti-Microbial Resistance Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
9.1. Technology Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.1.1. Microbiology Culture
9.1.2. Immunoassay
9.1.3. PCR
9.1.4. NGS
9.1.5. Mass Spectrometry
9.1.6. Rapid & Point of Care
9.1.7. Others
9.2. Pathogen Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Drug Resistant Streptococcus Pneumoniae (DRSP)
9.2.2. Drug Resistant Campylobacter (DRC)
9.2.3. Clostridium Difficile (CD)
9.2.4. Methicillin Resistant Staphylococcus Aureus (MRSA)
9.2.5. Drug Resistant Neisseria Gonorrhoeae (DRNG)
9.2.6. Drug Resistant Salmonella (DRNTS)
9.2.7. Others
9.3. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospitals
9.3.2. Diagnostic Laboratories
9.3.3. Pharmaceutical & Biotechnology Companies
9.3.4. Others
9.4. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Anti-Microbial Resistance Market - Opportunity Analysis Index, By Technology, Pathogen and Country, 2022 - 2028
9.6. North America Anti-Microbial Resistance Market Dynamics – Trends
10. Europe Anti-Microbial Resistance Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
10.1. Technology Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Microbiology Culture
10.1.2. Immunoassay
10.1.3. PCR
10.1.4. NGS
10.1.5. Mass Spectrometry
10.1.6. Rapid & Point of Care
10.1.7. Others
10.2. Pathogen Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Drug Resistant Streptococcus Pneumoniae (DRSP)
10.2.2. Drug Resistant Campylobacter (DRC)
10.2.3. Clostridium Difficile (CD)
10.2.4. Methicillin Resistant Staphylococcus Aureus (MRSA)
10.2.5. Drug Resistant Neisseria Gonorrhoeae (DRNG)
10.2.6. Drug Resistant Salmonella (DRNTS)
10.2.7. Others
10.3. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospitals
10.3.2. Diagnostic Laboratories
10.3.3. Pharmaceutical & Biotechnology Companies
10.3.4. Others
10.4. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Anti-Microbial Resistance Market - Opportunity Analysis Index, By Technology, Pathogen and Country, 2022 - 2028
10.6. Europe Anti-Microbial Resistance Market Dynamics – Trends
11. Asia-Pacific Anti-Microbial Resistance Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
11.1. Technology Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Microbiology Culture
11.1.2. Immunoassay
11.1.3. PCR
11.1.4. NGS
11.1.5. Mass Spectrometry
11.1.6. Rapid & Point of Care
11.1.7. Others
11.2. Pathogen Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Drug Resistant Streptococcus Pneumoniae (DRSP)
11.2.2. Drug Resistant Campylobacter (DRC)
11.2.3. Clostridium Difficile (CD)
11.2.4. Methicillin Resistant Staphylococcus Aureus (MRSA)
11.2.5. Drug Resistant Neisseria Gonorrhoeae (DRNG)
11.2.6. Drug Resistant Salmonella (DRNTS)
11.2.7. Others
11.3. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospitals
11.3.2. Diagnostic Laboratories
11.3.3. Pharmaceutical & Biotechnology Companies
11.3.4. Others
11.4. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Rest of Asia-Pacific
11.5. Asia-Pacific Anti-Microbial Resistance Market - Opportunity Analysis Index, By Technology, Pathogen and Country, 2022 - 2028
11.6. Asia-Pacific Anti-Microbial Resistance Market Dynamics – Trends
12. Latin America Anti-Microbial Resistance Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
12.1. Technology Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Microbiology Culture
12.1.2. Immunoassay
12.1.3. PCR
12.1.4. NGS
12.1.5. Mass Spectrometry
12.1.6. Rapid & Point of Care
12.1.7. Others
12.2. Pathogen Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Drug Resistant Streptococcus Pneumoniae (DRSP)
12.2.2. Drug Resistant Campylobacter (DRC)
12.2.3. Clostridium Difficile (CD)
12.2.4. Methicillin Resistant Staphylococcus Aureus (MRSA)
12.2.5. Drug Resistant Neisseria Gonorrhoeae (DRNG)
12.2.6. Drug Resistant Salmonella (DRNTS)
12.2.7. Others
12.3. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospitals
12.3.2. Diagnostic Laboratories
12.3.3. Pharmaceutical & Biotechnology Companies
12.3.4. Others
12.4. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Argentina
12.4.3. Rest of Latin America
12.5. Latin America Anti-Microbial Resistance Market - Opportunity Analysis Index, By Technology, Pathogen and Country, 2022 - 2028
12.6. Latin America Anti-Microbial Resistance Market Dynamics – Trends
13. Middle East and Africa Anti-Microbial Resistance Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million)
13.1. Technology Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.1.1. Microbiology Culture
13.1.2. Immunoassay
13.1.3. PCR
13.1.4. NGS
13.1.5. Mass Spectrometry
13.1.6. Rapid & Point of Care
13.1.7. Others
13.2. Pathogen Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Drug Resistant Streptococcus Pneumoniae (DRSP)
13.2.2. Drug Resistant Campylobacter (DRC)
13.2.3. Clostridium Difficile (CD)
13.2.4. Methicillin Resistant Staphylococcus Aureus (MRSA)
13.2.5. Drug Resistant Neisseria Gonorrhoeae (DRNG)
13.2.6. Drug Resistant Salmonella (DRNTS)
13.2.7. Others
13.3. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospitals
13.3.2. Diagnostic Laboratories
13.3.3. Pharmaceutical & Biotechnology Companies
13.3.4. Others
13.4. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Saudi Arabia
13.4.2. GCC Countries
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Anti-Microbial Resistance Market - Opportunity Analysis Index, By Technology, Pathogen and Country, 2022 - 2028
13.6. MEA Anti-Microbial Resistance Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Technology Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Abacus Diagnostica
14.2.2. Abbott Laboratories
14.2.3. Accelerate Diagnostics
14.2.4. ADT Biotech
14.2.5. Beckman Coulter Diagnostics
14.2.6. Becton, Dickinson and Company
14.2.7. Binx Health
14.2.8. bioMerieux Diagnostics
14.2.9. Bio-Rad Laboratories, Inc.
14.2.10. Cepheid (Danaher)
14.2.11. Curetis N.V./Curetis GmbH
14.2.12. Day Zero Diagnostics
14.2.13. Enzo Biochem
14.2.14. Eurofins Scientific
14.2.15. Fusion Genomics
14.2.16. GeneFluidics
14.2.17. Great Basin Corporation
14.2.18. Hologic
15. Research Methodology
16. Key Assumptions and Acronyms
  • Abacus Diagnostica
  • Abbott Laboratories
  • Accelerate Diagnostics
  • ADT Biotech
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • Binx Health
  • bioMerieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Cepheid (Danaher)
  • Curetis N.V./Curetis GmbH
  • Day Zero Diagnostics
  • Enzo Biochem
  • Eurofins Scientific
  • Fusion Genomics
  • GeneFluidics
  • Great Basin Corporation
  • Hologic

Adjacent Markets